三阴性乳腺癌的药物治疗现状及研究进展

三阴性乳腺癌(Triple-negative breast cancer,TNBC)是缺少雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体(HER-2)表达的乳腺癌,虽对放化疗敏感,但缺乏相应的靶向治疗及内分泌治疗,具有侵袭性强、复发风险高、预后差的特点。因此近些年来,三阴性乳腺癌受到越来越多的国际肿瘤学界的关注,对三阴性乳腺癌的深入研究,将有助于该病的预防、早期诊断、判断疾病进展以及改善预后。本文将近几年来有关三阴乳腺癌的药物治疗现状及研究进展予以综述。

Drug treatment status and research progress on triple-negative breast cancer

Triple negative breast cancer(TNBC)is defined by the lack of expressions of the estrogen receptor(ER)、progesterone receptor(PR)and human epidermal growth factor receptor 2(HER-2).Although it is sensitive to radiation and chemotherapy,it lacks of appropriate targeted therapy and endocrine therapy.It performs characteristics of the strong invasion,high risk of recurrence and poor prognosis.So in recent years,triple negative breast cancer gets more and more attention from international oncology community.In-depth study of triple negative breast cancer will help the prevention,early diagnosis,judge the progress of the disease and improve prognosis.TNBC drug treatment and relevant research progress are reviewed in the present article.